Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell crawled date : 2021 - 11 - 09 save search
Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies
Published: 2021-11-09 (Crawled : 20:00) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: -1.25%
H: 0.63%
C: -5.91%
cancer license t-cell
Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting
Published: 2021-11-09 (Crawled : 14:15) - biospace.com/
DTIL | $9.85 1.13% 1.12% 47K
|
Health Technology
|
| O: -2.04%
H: 0.0%
C: 0.0%
immunotherapy therapy cancer arcus car-t t-cell
SITC Abstract: IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion
Published: 2021-11-09 (Crawled : 13:15) - igmbio.com
IGMS | $6.765 -6.04% -6.43% 240K
|
Health Technology
|
| O: -4.19%
H: 0.0%
C: 0.0%
antibody t-cell
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.